Efficacy of First Line Bortezomib, Rituximab, Ibrutinib (B-RI) for Patients With Treatment Naive Waldenström's Macroglobulinemia
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Bortezomib (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 01 Oct 2019 Planned End Date changed from 1 Nov 2024 to 1 Sep 2029.
- 01 Oct 2019 Planned primary completion date changed from 1 Nov 2020 to 1 Mar 2022.
- 01 Oct 2019 Status changed from not yet recruiting to recruiting.